Immune checkpoint inhibitors have changed cancer care. These medicines release the brakes on the immune system so it can attack tumors such as melanoma. But an energized immune system can also inflame healthy tissue. A systematic review from the University of Adelaide, published in November 2026, gathered what is known about one rare side effect: inflammation in the orbit, the bony socket around the eye.
What the researchers did
The team searched five medical databases in September 2026 and found 57 published reports describing 81 patients who developed orbital inflammation during or after checkpoint inhibitor treatment.
What they found
- Median age was about 66, and 63% were men. Melanoma was the most common cancer (about 41%).
- Symptoms started a median of 6 weeks after treatment began.
- The most common signs were limited or painful eye movement and double vision (70%) and bulging eyes (30%). Both sides were affected in about 3 of 4 patients.
- The eye-moving muscles were inflamed in 83%. The tear gland and the optic nerve were rarely involved.
- About 17% looked like thyroid eye disease, even though most of those patients had normal thyroid tests.
- Two-thirds had immune side effects elsewhere, most often muscle inflammation (37%) and heart muscle inflammation (24%).
- Steroids were used in 93%, and about 40% needed additional immune-calming treatment. Symptoms fully or partly resolved in 88%; about 10% had a recurrence.
The authors concluded that this side effect has a distinct pattern and that its recognition should prompt urgent, team-based evaluation, including checks for heart and muscle involvement.
What this means for you
- If you are on immunotherapy and develop double vision, painful eye movement, eyelid swelling or bulging eyes, contact your oncology team the same day and arrange an eye exam.
- Mention any new muscle weakness, chest pain or shortness of breath at the same time. These can be related and serious.
- Do not stop cancer treatment on your own. Your oncologist and eye specialists will decide together.
For readable explanations of retinal and inflammatory eye conditions, see this retina education site.
Our office refers orbital inflammation to oculoplastic and oncology specialists. Early recognition is what protects both the eye and the patient.
Source: Immune checkpoint inhibitor-associated orbital inflammation: a systematic review (Graefe’s Archive for Clinical and Experimental Ophthalmology (PubMed), 11/06/2026). This article is an educational summary written by Khanna Vision Institute and is not a substitute for medical advice.
Leave a Reply